Lipocine (LPCN) Set to Release Quarterly Earnings on Thursday

Lipocine (NASDAQ:LPCN) is projected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Lipocine to announce earnings of ($0.39) per share and revenue of $0.16 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.08. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. The business had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.21 million. On average, analysts expect Lipocine to post ($1.54) EPS for the current fiscal year and ($1.03) EPS for the next fiscal year.

Lipocine Stock Up 0.7%

LPCN stock opened at $1.45 on Tuesday. Lipocine has a fifty-two week low of $1.36 and a fifty-two week high of $12.37. The firm’s 50-day simple moving average is $1.97 and its 200 day simple moving average is $3.95.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Lipocine in a research note on Tuesday, September 22nd. Weiss Ratings upgraded shares of Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Wall Street Zen upgraded shares of Lipocine from a “sell” rating to a “hold” rating in a research note on Saturday, July 18th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price target on shares of Lipocine in a report on Monday, September 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Lipocine has a consensus rating of “Hold” and an average target price of $4.00.

Insider Activity

In other Lipocine news, Director John Higuchi purchased 15,970 shares of the firm’s stock in a transaction dated Wednesday, September 30th. The stock was bought at an average price of $2.23 per share, with a total value of $35,613.10. Following the completion of the purchase, the director owned 241,365 shares in the company, valued at $538,243.95. This trade represents a 7.09% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders acquired a total of 37,568 shares of company stock valued at $82,174 over the last ninety days. Corporate insiders own 4.69% of the company’s stock.

About Lipocine

Lipocine Inc is a biopharmaceutical company focused on developing oral therapies for conditions with significant unmet medical needs. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and clinical performance of active pharmaceutical ingredients that may otherwise have limited effectiveness when taken orally.

Lipocine’s lead product is Tlando, an oral testosterone replacement therapy containing testosterone undecanoate. The U.S. Food and Drug Administration approved Tlando in 2022 for testosterone replacement therapy in adult males with hypogonadism associated with an underlying medical condition.